Role of TRPV4 and YAP/TAZ in Tendon Fibrosis and Engineered Tendon Development

TRPV4 和 YAP/TAZ 在肌腱纤维化和工程肌腱发育中的作用

基本信息

  • 批准号:
    10546427
  • 负责人:
  • 金额:
    $ 4.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract More than 300,000 rotator cuff surgeries occur annually in the US. However, treatment is often complicated by disorganized collagen matrix formed via fibrosis and results in high re-tear rates. Tendon tissue engineering seeks to solve the problem using biomaterials to promote neo-tendon formation to augment repair or regenerate tendon. However, while current biomaterials provide the opportunity to improve tendon healing, they frequently still exhibit fibrosis in preclinical studies. Therefore, a critical need exists to understand the mechanisms of aligned collagen formation when designing biomaterials for tendon tissue engineering. Matrix architecture and transient receptor potential cation channel subfamily V member 4 (TRPV4) regulate aligned collagen formation during tenogenesis in vitro, but the mechanism remains to be determined. Recently, TRPV4 stimulation was found to induce nuclear localization and activation of transcriptional co-activators Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in keratinocytes and myofibroblasts during fibrosis. YAP expression is upregulated during tendon development, a process characterized by aligned collagen formation, and in response to physiological mechanical stimulation, suggesting it could play an important role in tendon. Both TRPV4 and YAP/TAZ are dysregulated in lung, liver, kidney, and cardiac fibrosis. However, the role of TRPV4 and YAP/TAZ, and their interactions, have not been investigated in tendon fibrosis or during engineered tendon development. The overall hypothesis is that TRPV4 regulates collagen alignment via YAP/TAZ during tenogenesis on biomaterials and stimulates neo-tendon formation to a similar extent as tensile loading. In contrast, dysregulation of this relationship between YAP/TAZ and TRPV4 will promote fibrotic matrix deposition. Aim 1 will compare the role of YAP/TAZ and TRPV4 in healthy and fibrotic rotator cuff tendon. Aim 2 will investigate the interaction between TRPV4 and YAP/TAZ in aligned collagen formation during tenogenesis on electrospun biomaterials in ‘healthy’ and ‘fibrotic’ conditions. Aim 3 will evaluate how TRPV4 stimulation affects neo-tendon formation on biomaterials. This information will directly inform planned preclinical studies of rotator cuff repair initially in rodent models, before, if successful, moving to large animal models and clinical translation. Completing the proposed studies will provide me with the opportunities and training to support my career goals and develop the skills I need to achieve my long-term goal of an independent faculty career at a research-intensive institution.
项目总结/摘要 在美国,每年有超过30万例肩袖手术。然而,治疗往往是复杂的, 通过纤维化形成的无序胶原基质并导致高的再撕裂率。肌腱组织工程 寻求解决使用生物材料促进新肌腱形成以增强修复或再生的问题 肌腱然而,虽然目前的生物材料提供了改善肌腱愈合的机会,但它们经常 在临床前研究中仍然表现出纤维化。因此,迫切需要了解 在设计肌腱组织工程生物材料时,矩阵架构和 瞬时受体电位阳离子通道亚家族V成员4(TRPV4)调节排列胶原形成 在体外肌腱形成过程中,但其机制仍有待确定。最近,TRPV4刺激被 发现诱导核定位和转录辅激活因子Yes相关蛋白(雅普)的激活 在纤维化过程中,在角质形成细胞和肌成纤维细胞中与PDZ结合基序(TAZ)和转录共激活因子。 雅普表达在肌腱发育过程中上调,这一过程的特征是胶原蛋白的排列 形成,并响应生理机械刺激,这表明它可能发挥重要作用, 肌腱TRPV 4和雅普/TAZ在肺、肝、肾和心脏纤维化中均失调。但 TRPV 4和雅普/TAZ的作用以及它们之间的相互作用在肌腱纤维化中或 工程化肌腱开发。总体假设是TRPV4通过以下途径调节胶原排列: 雅普/TAZ在生物材料上的肌腱形成过程中,刺激新肌腱形成的程度与拉伸相似 加载中相反,雅普/TAZ和TRPV 4之间的这种关系的失调将促进纤维化基质 证词目的1将比较雅普/TAZ和TRPV 4在健康和纤维化肩袖肌腱中的作用。目的2 将研究TRPV 4和雅普/TAZ在肌腱形成过程中对齐胶原形成中的相互作用 在"健康"和"纤维化"条件下的静电纺丝生物材料。目标3将评价TRPV 4刺激 影响生物材料上的新肌腱形成。该信息将直接告知计划的临床前研究, 肩袖修复最初在啮齿动物模型中进行,如果成功,则转移到大型动物模型和临床 翻译.完成拟议的研究将为我提供机会和培训,以支持我的 职业目标和发展的技能,我需要实现我的长期目标,一个独立的教师职业生涯在一个 研究密集型机构。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tendon-derived matrix crosslinking techniques for electrospun multi-layered scaffolds.
  • DOI:
    10.1002/jbm.a.37588
  • 发表时间:
    2023-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Thomas L Jenkins;Paula A Sarmiento Huertas;Kentaro Umemori;F. Guilak;D. Little
  • 通讯作者:
    Thomas L Jenkins;Paula A Sarmiento Huertas;Kentaro Umemori;F. Guilak;D. Little
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas Lee Jenkins其他文献

Synthetic scaffolds for musculoskeletal tissue engineering: cellular responses to fiber parameters
用于肌肉骨骼组织工程的合成支架:对纤维参数的细胞反应
  • DOI:
    10.1038/s41536-019-0076-5
  • 发表时间:
    2019-06-27
  • 期刊:
  • 影响因子:
    6.500
  • 作者:
    Thomas Lee Jenkins;Dianne Little
  • 通讯作者:
    Dianne Little

Thomas Lee Jenkins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas Lee Jenkins', 18)}}的其他基金

Role of TRPV4 and YAP/TAZ in Tendon Fibrosis and Engineered Tendon Development
TRPV4 和 YAP/TAZ 在肌腱纤维化和工程肌腱发育中的作用
  • 批准号:
    10312447
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了